EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	134.73M
Revenue (ttm)	50.22M
Net Income (ttm)	6.12M
Shares Out	449.09M
EPS (ttm)	0.01
PE Ratio	22.21
Forward PE	21.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,228,281
Average Volume	476,125
Open	30.80
Previous Close	30.30
Day's Range	29.87 - 30.80
52-Week Range	18.40 - 32.00
Beta	0.20
RSI	55.58
Earnings Date	Sep 16, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 303
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.